Acquisition valued at $2.9 billion.
Soleno Therapeutics has an approved medicine for a rare disease.
The rare disease causes insatiable hunger.
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Strategic angle: Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion, gaining access to a treatment for a rare disease linked to insatiable hunger.